Top

Published in:

Open Access 01-12-2014 | Review

How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?

Authors: Gloria Wong, Fekade Bruck Sime, Jeffrey Lipman, Jason A Roberts

Published in: BMC Infectious Diseases | Issue 1/2014

Abstract

High mortality and morbidity rates associated with severe infections in the critically ill continue to be a significant issue for the healthcare system. In view of the diverse and unique pharmacokinetic profile of drugs in this patient population, there is increasing use of therapeutic drug monitoring (TDM) in attempt to optimize the exposure of antibiotics, improve clinical outcome and minimize the emergence of antibiotic resistance. Despite this, a beneficial clinical outcome for TDM of antibiotics has only been demonstrated for aminoglycosides in a general hospital patient population. Clinical outcome studies for other antibiotics remain elusive. Further, there is significant variability among institutions with respect to the practice of TDM including the selection of patients, sampling time for concentration monitoring, methodologies of antibiotic assay, selection of PK/PD targets as well as dose optimisation strategies. The aim of this paper is to review the available evidence relating to practices of antibiotic TDM, and describe how TDM can be applied to potentially improve outcomes from severe infections in the critically ill.

Bellomo R: Mortality in severe sepsis: an inconvenient truth. Crit Care Resusc. 2010, 12 (1): 6-8.PubMed

Boussekey N, Cantrel J, Dorchin Debrabant L, Langlois J, Devos P, Meybeck A, Chiche A, Georges H, Leroy O: Epidemiology, prognosis, and evolution of management of septic shock in a French intensive care unit: a five years survey. Crit Care Res Pract. 2010, 2010: 436427-PubMedPubMedCentral

Melamed A, Sorvillo FJ: The burden of sepsis-associated mortality in the United States from 1999 to 2005: an analysis of multiple-cause-of-death data. Crit Care. 2009, 13 (1): R28-PubMedPubMedCentral

Vincent J-L, Rello J, Marchall JC, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall CD, Sakr Y, Reinhart K: International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009, 302 (21): 2323-2329.PubMed

Roberts J, Abdul Aziz M, Lipman J, Mouton J, Vinks A, Felton T, Hope W, Farkas A, Neely M, Schentag J, Drusano G, Frey OR, Theuretzbacher U, Kuti JL, on behalf of The International Society of Anti-Infective Pharmacology and the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases: Individualised antibiotic dosing for patients who are critically ill challenges and potential solutions. Lancet Inf Dis. 2014, 14 (6): 498-509.

Taccone FS, Laterre P-F, Dugernier T, Spapen H, Delattre IK, Wittebole X, De Backer D, Layeux B, Wallemacq P, Vincent J-L, Jacobs F: Insufficient beta-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care. 2010, 14 (4): R126-PubMedPubMedCentral

Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, Kaukonen KM, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Lipman J, DALI Study: DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients?. Clin Infect Dis. 2014, 58 (8): 1072-1083.PubMed

Rea RS, Capitano B, Bies R, Bigos KL, Smith R, Lee H: Suboptimal aminoglycoside dosing in critically ill patients. Ther Drug Monit. 2008, 30 (6): 674-681.PubMed

Roberts JA, Taccone FS, Udy AA, Vincent JL, Jacobs F, Lipman J: Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens. Antimicrob Agents Chemother. 2011, 55 (6): 2704-2709.PubMedPubMedCentral

10.

van Zanten AR, Polderman KH, van Geijlswijk IM, van der Meer GY, Schouten MA, Girbes AR: Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. J Crit Care. 2008, 23 (3): 422-430.PubMed

11.

Swoboda S, Ober MC, Lichtenstern C, Saleh S, Schwenger V, Sonntag HG, Haefeli WE, Hempel G, Hoppe-Tichy T, Weigand MA: Pharmacokinetics of linezolid in septic patients with and without extended dialysis. Eur J Clin Pharmacol. 2010, 66 (3): 291-298.PubMed

12.

Taccone FS, Cotton F, Roisin S, Vincent J-L, Jacobs F: Optimal meropenem concentrations to treat multidrug-resistant pseudomonas aeruginosa septic shock. Antimicrob Agents Chemother. 2012, 56 (4): 2129-2131.PubMedPubMedCentral

13.

Tam VH, Rogers CA, Chang KT, Weston JS, Caeiro JP, Garey KW: Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrob Agents Chemother. 2010, 54 (9): 3717-3722.PubMedPubMedCentral

14.

Wegner C, Hubner NO, Gleich S, Thalmaier U, Kruger CM, Kramer A: One-day point prevalence of emerging bacterial pathogens in a nationwide sample of 62 German hospitals in 2012 and comparison with the results of the one-day point prevalence of 2010. GMS Hyg Infect Control. 2013, 8 (1): Doc12-PubMedPubMedCentral

15.

Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006, 34 (6): 1589-1596.PubMed

16.

Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, Dalovisio JR, Levine DP: Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2009, 49 (3): 325-327.PubMed

17.

Kullar R, Davis SL, Levine DP, Rybak MJ: Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis. 2011, 52 (8): 975-981.PubMed

18.

McKinnon PS, Paladino JA, Schentag JJ: Evaluation of Area Under the Inhibitory Curve (AUIC) and Time Above the Minimum Inhibitory Concentration (T > MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents. 2008, 31 (4): 345-351.PubMed

19.

van Lent-Evers NA, Mathôt RA, Geus WP, van Hout BA, Vinks AA: Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. Ther Drug Monit. 1999, 21 (1): 63-73.PubMed

20.

Lacy MK, Nicolau DP, Nightingale CH, Quintiliani R: The pharmacodynamics of aminoglycosides. Clin Infect Dis. 1998, 27 (1): 23-27.PubMed

21.

Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ: Pharmacodynamics of intravenous ciprofloxacin in seriously Ill patients. Antimicrob Agents Chemother. 1993, 37 (5): 1073-1081.PubMedPubMedCentral

22.

Wong G, Brinkman A, Benefield RJ, Carlier M, De Waele JJ, El Helali N, Frey O, Harbarth S, Huttner A, McWhinney B, Misset B, Pea F, Preisenberger J, Roberts MS, Robertson TA, Roehr A, Sime FB, Taccone FS, Ungerer JP, Lipman J, Roberts JA: An international, multicentre survey of beta-lactam antibiotic therapeutic drug monitoring practice in intensive care units. J Antimicrob Chemother. 2014, 69 (5): 1416-1423.PubMed

23.

Roberts JA, Norris R, Paterson DL, Martin JH: Therapeutic drug monitoring of antimicrobials. Br J Clin Pharmacol. 2012, 73 (1): 27-36.PubMedPubMedCentral

24.

Dong H, Wang X, Dong Y, Lei J, Li H, You H, Wang M, Xing J, Sun J, Zhu H: Clinical pharmacokinetic/pharmacodynamic profile of linezolid in severely ill intensive care unit patients. Int J Antimicrob Agents. 2011, 38 (4): 296-300.PubMed

25.

Udy AA, Roberts JA, De Waele JJ, Paterson DL, Lipman J: What’s behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance. Int J Antimicrob Agents. 2012, 39 (6): 455-457.PubMed

26.

Udy AA, Varghese JM, Altukroni M, Briscoe S, McWhinney B, Ungerer J, Lipman J, Roberts JA: Sub-therapeutic initial β-lactam concentrations in select critically ill patients. Chest. 2012, 142 (1): 30-39.PubMed

27.

Kielstein JT, Burkhardt O: Dosing of antibiotics in critically ill patients undergoing renal replacement therapy. Curr Pharm Biotechnol. 2011, 12 (12): 2015-2019.PubMed

28.

Jamal J-A, Economou CJP, Lipman J, Roberts JA: Improving antibiotic dosing in special situations in the ICU: burns, renal replacement therapy and extracorporeal membrane oxygenation. Curr Opin Crit Care. 2012, 18 (5): 460-471.PubMed

29.

Shekar K, Fraser JF, Smith MT, Roberts JA: Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation. J Crit Care. 2012, 27: 741-e749–e718PubMed

30.

Choi GYS, Gomersall CD, Tian Q, Joynt GM, Freebairn R, Lipman J: Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med. 2009, 37: 2268-2282.PubMed

31.

Tam VH, Gamez EA, Weston JS, Gerard LN, Larocco MT, Caeiro JP, Gentry LO, Garey KW: Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis. 2008, 46 (6): 862-867.PubMed

32.

Weisenberg SA, Morgan DJ, Espinal-Witter R, Larone DH: Clinical outcomes of patients with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae after treatment with imipenem or meropenem. Diagn Microbiol Infect Dis. 2009, 64 (2): 233-235.PubMedPubMedCentral

33.

Bhat SV, Peleg AY, Lodise TPJ, Shutt KA, Capitano B, Potoski BA, Paterson DL: Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms. Antimicrob Agents Chemother. 2007, 51 (12): 4390-4395.PubMedPubMedCentral

34.

Vading M, Samuelsen O, Haldorsen B, Sundsfjord AS, Giske CG: Comparison of disk diffusion, Etest and VITEK2 for detection of carbapenemase-producing Klebsiella pneumoniae with the EUCAST and CLSI breakpoint systems. Clin Microbiol Infect. 2011, 17 (5): 668-674.PubMed

35.

Kitzis M: Antibiotic assay. Antibiogram. Edited by: Courvalin P, Leclercq R, Rice LB. 2010, Portland, Oregon: ESKA Publishing, ASM Press, 75-88. 3

36.

Sime FB, Roberts MS, Peake SL, Lipman J, Roberts JA: Does beta-lactam pharmacokinetic variability in critically ill patients justify therapeutic drug monitoring? A systematic review. Ann Intensive Care. 2012, 2 (1): 35-PubMedPubMedCentral

37.

Tam VH, McKinnon PS, Akins RL, Rybak MJ, Drusano GL: Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother. 2002, 50 (3): 425-428.PubMed

38.

Roberts JA, Ulldemolins M, Roberts MS, McWhinney B, Ungerer J, Paterson DL, Lipman J: Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents. 2010, 36: 332-339.PubMed

39.

Pea F, Viale P, Cojutti P, Furlanut M: Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: a pharmacokinetics/pharmacodynamics-based approach. Antimicrob Agents Chemother. 2012, 56 (12): 6343-6348.PubMedPubMedCentral

40.

Roberts JA, Kirkpatrick CMJ, Roberts MS, Dalley AJ, Lipman J: First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents. 2010, 35 (2): 156-163.PubMed

41.

Lee GC, Liou H, Yee R, Quan CF, Neldner K: Outcomes of extended-infusion piperacillin-tazobactam: a retrospective analysis of critically ill patients. Clin Ther. 2012, 34 (12): 2297-2300.PubMed

42.

Dulhunty JM, Roberts JA, Davis JS, Webb SA, Bellomo R, Gomersall C, Shirwadkar C, Eastwood GM, Myburgh J, Paterson DL, Starr T, Udy AA, Paul SK, Lipman J, Australian and New Zealand Intensive Care Society Clinical Trials Group: A protocol for a multicentre randomised controlled trial of continuous beta-lactam infusion compared with intermittent beta-lactam dosing in critically ill patients with severe sepsis: the BLING II study. Crit Care Resusc. 2013, 15 (3): 179-185.PubMed

43.

Pea F, Cojutti P, Sbrojavacca R, Cadeo B, Cristini F, Bulfoni A, Furlanut M: TDM-guided therapy with daptomycin and meropenem in a morbidly obese. Critically ill patient. Ann Pharmacother. 2011, 45: e37-PubMed

44.

Lamoth F, Buclin T, Pascual A, Vora S, Bolay S, Decosterd LA, Calandra T, Marchetti O: High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function. Antimicrob Agents Chemother. 2010, 54 (10): 4360-4367.PubMedPubMedCentral

45.

Lonsdale DO, Udy AA, Roberts JA, Lipman J: Antibacterial therapeutic drug monitoring in cerebrospinal fluid: difficulty in achieving adequate drug concentrations. J Neurosurg. 2013, 118 (2): 297-301.PubMed

46.

Chapuis TM, Giannoni E, Majcherczyk PA, Chiolero R, Schaller M-D, Berger MM, Bolay S, Decosterd LA, Bugnon D, Moreillon P: Prospective monitoring of cefepime in intensive care unit adult patients. Crit Care. 2010, 14 (2): R51-PubMedPubMedCentral

47.

Simon N, Dussol B, Sampol E, Purgus R, Brunet P, Lacarelle B, Berland Y, Bruguerolle B, Urien S: Population pharmacokinetics of ceftriaxone and pharmacodynamic considerations in haemodialysed patients. Clin Pharmacokinet. 2006, 45 (5): 493-501.PubMed

48.

Seyler L, Cotton F, Taccone FS, De Backer D, Macours P, Vincent J-L, Jacobs F: Recommended beta-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy. Crit Care. 2011, 15: R137-PubMedPubMedCentral

49.

Carlier M, Stove V, Roberts JA, Van de Velde E, De Waele JJ, Verstraete AG: Quantification of seven beta-lactam antibiotics and two beta-lactamase inhibitors in human plasma using a validated UPLC-MS/MS method. Int J Antimicrob Agents. 2012, 40 (5): 416-422.PubMed

50.

Ohmori T, Suzuki A, Niwa T, Ushikoshi H, Shirai K, Yoshida S, Ogura S, Itoh Y: Simultaneous determination of eight beta-lactam antibiotics in human serum by liquid chromatography–tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2011, 879: 1038-1042.PubMed

51.

Mendez AS, Steppe M, Schapoval EE: Validation of HPLC and UV spectrophotometric methods for the determination of meropenem in pharmaceutical dosage form. J Chromatogr B Analyt Technol Biomed Life Sci. 2003, 33: 947-954.

52.

McWhinney B, Wallis SC, Hillister T, Roberts JA, Lipman J, Ungerer J: Analysis of 12 beta-lactam antibiotics in human plasma by HPLC with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2010, 878: 2036-2043.

53.

Briscoe S, McWhinney B, Lipman J, Roberts JA, Ungerer JP: A method for determining the free (unbound) concentration of ten beta-lactam antibiotics in human plasma using high performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2012, 907: 178-184.PubMed

54.

Wong G, Briscoe S, Adnan S, McWhinney B, Ungerer J, Lipman J, Roberts JA: Protein binding of beta-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations?. Antimicrob Agents Chemother. 2013, 57 (12): 6165-6170.PubMedPubMedCentral

55.

Farkas A, Daroczi G: Individually Designed Optimum Dosing Strategies (ID-ODS): A Multi-Model Based Online Application to Individualize Antibiotic Dosing in Critically Ill Patients. Proceedings of NewYork-Presbyterian Healthcare System Quality Symposium. Edited by: Osten WM, Lazar EJ, Regan BK. 2013, New York: The NewYork-Presbyterian, 240-

56.

Barclay ML, Kirkpatrick CM, Begg EJ: Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored?. Clin Pharmacokinet. 1999, 36 (2): 89-98.PubMed

57.

Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R: Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995, 39 (3): 650-655.PubMedPubMedCentral

58.

Bartal C, Danon A, Schlaeffer F, Reisenberg K, Alkan M, Smoliakov R, Sidi A, Almog Y: Pharmacokinetic dosing of aminoglycosides: a controlled trial. Am J Med. 2003, 114 (3): 194-198.PubMed

59.

Streetman DS, Nafziger AN, Destache CJ, Bertino AS: Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs. Pharmacotherapy. 2001, 21 (4): 443-451.PubMed

60.

Sanchez-Alcaraz A, Vargas A, Quintana MB, Rocher A, Querol JM, Poveda JL, Hermenegildo M: Therapeutic drug monitoring of tobramycin: once-daily versus twice-daily dosage schedules. J Clin Pharm Ther. 1998, 23 (5): 367-373.PubMed

61.

Conil JM, Georges B, Ruiz S, Rival T, Seguin T, Cougot P, Fourcade O, Pharmd GH, Saivin S: Tobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations. Br J Clin Pharmacol. 2011, 71 (1): 61-71.PubMedPubMedCentral

62.

Taccone FS, Laterre PF, Spapen H, Dugernier T, Delattre I, Layeux B, De Backer D, Wittebole X, Wallemacq P, Vincent JL, Jacobs F: Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care. 2010, 14 (2): R53-PubMedPubMedCentral

63.

Conil JM, Georges B, Breden A, Segonds C, Lavit M, Seguin T, Coley N, Samii K, Chabanon G, Houin G, Saivin S: Increased amikacin dosage requirements in burn patients receiving a once-daily regimen. Int J Antimicrob Agents. 2006, 28 (3): 226-230.PubMed

64.

Bracco D, Landry C, Dubois MJ, Eggimann P: Pharmacokinetic variability of extended interval tobramycin in burn patients. Burns. 2008, 34 (6): 791-796.PubMed

65.

Petejova N, Zahalkova J, Duricova J, Kacirova I, Brozmanova H, Urbanek K, Grundmann M, Martinek A: Gentamicin pharmacokinetics during continuous venovenous hemofiltration in critically ill septic patients. J Chemother. 2012, 24 (2): 107-112.PubMed

66.

Boyer A, Gruson D, Bouchet S, Clouzeau B, Hoang-Nam B, Vargas F, Gilles H, Molimard M, Rogues AM, Moore N: Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk. Drug Saf. 2013, 36 (4): 217-230.PubMed

67.

Mueller EW, Boucher BA: The use of extended-interval aminoglycoside dosing strategies for the treatment of moderate-to-severe infections encountered in critically ill surgical patients. Surg Infect (Larchmt). 2009, 10 (6): 563-570.

68.

Prins JM, Weverling GJ, de Blok K, van Ketel RJ, Speelman P: Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy. Antimicrob Agents Chemother. 1996, 40 (11): 2494-2499.PubMedPubMedCentral

69.

Wallace AW, Jones M, Bertino JS: Evaluation of four once-daily aminoglycoside dosing nomograms. Pharmacotherapy. 2002, 22 (9): 1077-1083.PubMed

70.

Botha FJ, van der Bijl P, Seifart HI, Parkin DP: Fluctuation of the volume of distribution of amikacin and its effect on once-daily dosage and clearance in a seriously ill patient. Intensive Care Med. 1996, 22 (5): 443-446.PubMed

71.

Begg EJ, Barclay ML, Duffull SB: A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol. 1995, 39 (6): 605-609.PubMedPubMedCentral

72.

Fonge H, Kaale E, Govaerts C, Desmet K, Van Schepdael A, Hoogmartens J: Bioanalysis of tobramycin for therapeutic drug monitoring by solid-phase extraction and capillary zone electrophoresis. J Chromatogr B Analyt Technol Biomed Life Sci. 2004, 810 (2): 313-318.PubMed

73.

Dasgupta A: Advances in antibiotic measurement. Adv Clin Chem. 2012, 56: 75-104.PubMed

74.

Avent ML, Teoh J, Lees J, Eckert KA, Kirkpatrick CM: Comparing 3 methods of monitoring gentamicin concentrations in patients with febrile neutropenia. Ther Drug Monit. 2011, 33 (5): 592-601.PubMed

75.

Delattre IK, Musuamba FT, Nyberg J, Taccone FS, Laterre PF, Verbeeck RK, Jacobs F, Wallemacq PE: Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients. Ther Drug Monit. 2010, 32 (6): 749-756.PubMed

76.

Turnidge J: Pharmacodynamics and dosing of aminoglycosides. Infect Dis Clin. 2003, 17 (3): 503-528.

77.

Minejima E, Choi J, Beringer P, Lou M, Tse E, Wong-Beringer A: Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients. Antimicrob Agents Chemother. 2011, 55 (7): 3278-3283.PubMedPubMedCentral

78.

Prabaker KK, Tran TP, Pratummas T, Goetz MB, Graber CJ: Elevated vancomycin trough is not associated with nephrotoxicity among inpatient veterans. J Hosp Med. 2012, 7 (2): 91-97.PubMed

79.

Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A: High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med. 2006, 166 (19): 2138-2144.PubMed

80.

Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef MH: A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther. 2007, 29 (6): 1107-1115.PubMed

81.

Lodise TP, Lomaestro B, Graves J, Drusano GL: Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother. 2008, 52 (4): 1330-1336.PubMedPubMedCentral

82.

Bosso JA, Nappi J, Rudisill C, Wellein M, Bookstaver PB, Swindler J, Mauldin PD: Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial. Antimicrob Agents Chemother. 2011, 55 (12): 5475-5479.PubMedPubMedCentral

83.

Pritchard L, Baker C, Leggett J, Sehdev P, Brown A, Bayley KB: Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity. Am J Med. 2010, 123 (12): 1143-1149.PubMed

84.

Hermsen ED, Hanson M, Sankaranarayanan J, Stoner JA, Florescu MC, Rupp ME: Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections. Expert Opin Drug Saf. 2010, 9 (1): 9-14.PubMed

85.

van Hal SJ, Paterson DL, Lodise TP: Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother. 2013, 57 (2): 734-744.PubMedPubMedCentral

86.

Forouzesh A, Moise PA, Sakoulas G: Vancomycin ototoxicity: a reevaluation in an era of increasing doses. Antimicrob Agents Chemother. 2009, 53 (2): 483-486.PubMed

87.

Shields RK, Martello JL, Potoski BA: Is vancomycin ototoxicity a significant risk?. Antimicrob Agents Chemother. 2009, 53 (10): 4572-author reply 4572–4573PubMedPubMedCentral

88.

Jeffres MN, Isakow W, Doherty JA, McKinnon PS, Ritchie DJ, Micek ST, Kollef MH: Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest. 2006, 130 (4): 947-955.PubMed

89.

Iwamoto T, Kagawa Y, Kojima M: Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin. Biol Pharm Bull. 2003, 26 (6): 876-879.PubMed

90.

Cheong JY, Makmor-Bakry M, Lau CL, Abdul Rahman R: The relationship between trough concentration of vancomycin and effect on methicillin-resistant Staphylococcus aureus in critically ill patients. S Afr Med J. 2012, 102 (7): 616-619.PubMed

91.

Ye ZK, Tang HL, Zhai SD: Benefits of therapeutic drug monitoring of vancomycin: a systematic review and meta-analysis. PLoS One. 2013, 8 (10): e77169-PubMedPubMedCentral

92.

Sakoulas G, Gold HS, Cohen RA, Venkataraman L, Moellering RC, Eliopoulos GM: Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia. J Antimicrob Chemother. 2006, 57 (4): 699-704.PubMed

93.

Howden BP, Ward PB, Charles PG, Korman TM, Fuller A, du Cros P, Grabsch EA, Roberts SA, Robson J, Read K, Bak N, Hurley J, Johnson PD, Morris AJ, Mayall BC, Grayson ML: Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis. 2004, 38 (4): 521-528.PubMed

94.

Moellering RC: Monitoring serum vancomycin levels: climbing the mountain because it is there?. Clin Infect Dis. 1994, 18 (4): 544-546.PubMed

95.

Rybak M, Lomaestro B, Rotschafer JC, Moellering R, Craig W, Billeter M, Dalovisio JR, Levine DP: Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009, 66 (1): 82-98.PubMed

96.

Potoski BA, Paterson DL: Appropriate pharmacokinetic index for outcome in Staphylococcus aureus pneumonia. Chest. 2007, 132 (3): 1101-1102. author reply 1102–1103PubMed

97.

Morrison AP, Melanson SE, Carty MG, Bates DW, Szumita PM, Tanasijevic MJ: What proportion of vancomycin trough levels are drawn too early? Frequency and impact on clinical actions. Am J Clin Pathol. 2012, 137 (3): 472-478.PubMed

98.

Takahashi Y, Takesue Y, Takubo S, Ishihara M, Nakajima K, Tsuchida T, Ikeuchi H, Uchino M: Preferable timing of therapeutic drug monitoring in patients with impaired renal function treated with once-daily administration of vancomycin. J Infect Chemother. 2013, 19 (4): 709-716.PubMed

99.

Tobin CM, Darville JM, Thomson AH, Sweeney G, Wilson JF, MacGowan AP, White LO: Vancomycin therapeutic drug monitoring: is there a consensus view? The results of a UK National External Quality Assessment Scheme (UK NEQAS) for antibiotic assays questionnaire. J Antimicrob Chemother. 2002, 50 (5): 713-718.PubMed

100.

Matsumoto K, Takesue Y, Ohmagari N, Mochizuki T, Mikamo H, Seki M, Takakura S, Tokimatsu I, Takahashi Y, Kasahara K, Okada K, Igarashi M, Kobayashi M, Hamada Y, Kimura M, Nishi Y, Tanigawara Y, Kimura T: Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J Infect Chemother. 2013, 19 (3): 365-380.PubMed

101.

Wilson JF, Davis AC, Tobin CM: Evaluation of commercial assays for vancomycin and aminoglycosides in serum: a comparison of accuracy and precision based on external quality assessment. J Antimicrob Chemother. 2003, 52 (1): 78-82.PubMed

102.

Murphy JE, Gillespie DE, Bateman CV: Predictability of vancomycin trough concentrations using seven approaches for estimating pharmacokinetic parameters. Am J Health Syst Pharm. 2006, 63 (23): 2365-2370.PubMed

103.

DeRyke CA, Alexander DP: Optimizing vancomycin dosing through pharmacodynamic assessment targeting area under the concentration-time curve/minimum inhibitory concentration. Hosp Pharm. 2009, 44 (9): 751-765.

104.

Pea F, Bertolissi M, Di Silvestre A, Poz D, Giordano F, Furlanut M: TDM coupled with Bayesian forecasting should be considered an invaluable tool for optimizing vancomycin daily exposure in unstable critically ill patients. Int J Antimicrob Agents. 2002, 20 (5): 326-332.PubMed

105.

Avent ML, Vaska VL, Rogers BA, Cheng AC, van Hal SJ, Holmes NE, Howden BP, Paterson DL: Vancomycin therapeutics and monitoring: a contemporary approach. Intern Med J. 2013, 43 (2): 110-119.PubMed

106.

Man SS, Carr RR, Ensom MH: Comparison of continuous and intermittent IV infusion of vancomycin: systematic review. Can J Hosp Pharm. 2010, 63 (5): 373-381.PubMedPubMedCentral

107.

James JK, Palmer SM, Levine DP, Rybak MJ: Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections. Antimicrob Agents Chemother. 1996, 40 (3): 696-700.PubMedPubMedCentral

108.

Wysocki M, Delatour F, Faurisson F, Rauss A, Pean Y, Misset B, Thomas F, Timsit JF, Similowski T, Mentec H, Mier L, Dreyfuss D: Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother. 2001, 45 (9): 2460-2467.PubMedPubMedCentral

109.

DiMondi VP, Rafferty K: Review of continuous-infusion vancomycin. Ann Pharmacother. 2013, 47 (2): 219-227.PubMed

110.

Panday PN, Sturkenboom M: Continuous infusion of vancomycin less effective and safe than intermittent infusion, based on pharmacodynamic and pharmacokinetic principles. Clin Infect Dis. 2009, 49 (12): 1964-1965. author reply 1965PubMed

111.

Jeurissen A, Sluyts I, Rutsaert R: A higher dose of vancomycin in continuous infusion is needed in critically ill patients. Int J Antimicrob Agents. 2011, 37 (1): 75-77.PubMed

112.

De Waele JJ, Danneels I, Depuydt P, Decruyenaere J, Bourgeois M, Hoste E: Factors associated with inadequate early vancomycin levels in critically ill patients treated with continuous infusion. Int J Antimicrob Agents. 2013, 41 (5): 434-438.PubMed

113.

Saugel B, Nowack MC, Hapfelmeier A, Umgelter A, Schultheiss C, Thies P, Phillip V, Eyer F, Schmid RM, Huber W: Continuous intravenous administration of vancomycin in medical intensive care unit patients. J Crit Care. 2013, 28 (1): 9-13.PubMed

114.

Ampe E, Delaere B, Hecq JD, Tulkens PM, Glupczynski Y: Implementation of a protocol for administration of vancomycin by continuous infusion: pharmacokinetic, pharmacodynamic and toxicological aspects. Int J Antimicrob Agents. 2013, 41 (5): 439-446.PubMed

115.

Cataldo MA, Tacconelli E, Grilli E, Pea F, Petrosillo N: Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. J Antimicrob Chemother. 2012, 67 (1): 17-24.PubMed

116.

Stalker DJ, Jungbluth GL: Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet. 2003, 42 (13): 1129-1140.PubMed

117.

Tsuji Y, Hiraki Y, Mizoguchi A, Hayashi W, Kamohara R, Kamimura H, Karube Y: Pharmacokinetics of repeated dosing of linezolid in a hemodialysis patient with chronic renal failure. J Infect Chemother. 2008, 14 (2): 156-160.PubMed

118.

Tsuji Y, Hiraki Y, Matsumoto K, Mizoguchi A, Kobayashi T, Sadoh S, Morita K, Kamimura H, Karube Y: Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction. J Infect Chemother. 2011, 17 (1): 70-75.PubMed

119.

Matsumoto K, Takeshita A, Ikawa K, Shigemi A, Yaji K, Shimodozono Y, Morikawa N, Takeda Y, Yamada K: Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction. Int J Antimicrob Agents. 2010, 36 (2): 179-181.PubMed

120.

Nukui Y, Hatakeyama S, Okamoto K, Yamamoto T, Hisaka A, Suzuki H, Yata N, Yotsuyanagi H, Moriya K: High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia. J Antimicrob Chemother. 2013, 68 (9): 2128-2133.PubMed

121.

Sousa R, Lopez R, Martinez-Pastor JC, Cervera C, Bori G, Garcia-Ramiro S, Mensa J, Soriano A: Usefulness of monitoring linezolid trough serum concentration in prolonged treatments. Rev Esp Quimioter. 2011, 24 (3): 151-153.PubMed

122.

Pea F, Furlanut M, Cojutti P, Cristini F, Zamparini E, Franceschi L, Viale P: Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. Antimicrob Agents Chemother. 2010, 54 (11): 4605-4610.PubMedPubMedCentral

123.

Hallam MJ, Allen JM, James SE, Donaldson PM, Davies JG, Hanlon GW, Dheansa BS: Potential subtherapeutic linezolid and meropenem antibiotic concentrations in a patient with severe burns and sepsis. J Burn Care Res. 2010, 31 (1): 207-209.PubMed

124.

Lovering AM, Le Floch R, Hovsepian L, Stephanazzi J, Bret P, Birraux G, Vinsonneau C: Pharmacokinetic evaluation of linezolid in patients with major thermal injuries. J Antimicrob Chemother. 2009, 63 (3): 553-559.PubMed

125.

Pea F, Scudeller L, Lugano M, Baccarani U, Pavan F, Tavio M, Furlanut M, Rocca GD, Bresadola F, Viale P: Hyperlactacidemia potentially due to linezolid overexposure in a liver transplant recipient. Clin Infect Dis. 2006, 42 (3): 434-435.PubMed

126.

Pea F, Viale P, Lugano M, Pavan F, Scudeller L, Della Rocca G, Furlanut M: Linezolid disposition after standard dosages in critically ill patients undergoing continuous venovenous hemofiltration: a report of 2 cases. Am J Kidney Dis. 2004, 44 (6): 1097-1102.PubMed

127.

Pea F, Cojutti P, Pagotto A, Cristini F, Furlanut M, Viale P: Successful long-term treatment of cerebral nocardiosis with unexpectedly low doses of linezolid in an immunocompromised patient receiving complex polytherapy. Antimicrob Agents Chemother. 2012, 56 (6): 3438-3440.PubMedPubMedCentral

128.

Polillo M, Tascini C, Lastella M, Malacarne P, Ciofi L, Viaggi B, Bocci G, Menichetti F, Danesi R, Del Tacca M, Di Paolo A: A rapid high-performance liquid chromatography method to measure linezolid and daptomycin concentrations in human plasma. Ther Drug Monit. 2010, 32 (2): 200-205.PubMed

129.

Alffenaar JW, Kosterink JG, van Altena R, van der Werf TS, Uges DR, Proost JH: Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis. Ther Drug Monit. 2010, 32 (1): 97-101.PubMed

130.

Cattaneo D, Baldelli S, Conti F, Cozzi V, Clementi E: Determination of linezolid in human plasma by high-performance liquid chromatography with ultraviolet detection. Ther Drug Monit. 2010, 32 (4): 520-524.PubMed

131.

Baietto L, D’Avolio A, Ariaudo A, Corcione S, Simiele M, Cusato J, Urbino R, Di Perri G, Ranieri VM, De Rosa FG: Development and validation of a new UPLC-PDA method to quantify linezolid in plasma and in dried plasma spots. J Chromatogr B Analyt Technol Biomed Life Sci. 2013, 936: 42-47.PubMed

132.

Vu DH, Bolhuis MS, Koster RA, Greijdanus B, de Lange WC, van Altena R, Brouwers JR, Uges DR, Alffenaar JW: Dried blood spot analysis for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2012, 56 (11): 5758-5763.PubMedPubMedCentral

133.

Bolhuis MS, van Altena R, van Hateren K, de Lange WC, Greijdanus B, Uges DR, Kosterink JG, van der Werf TS, Alffenaar JW: Clinical validation of the analysis of linezolid and clarithromycin in oral fluid of patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2013, 57 (8): 3676-3680.PubMedPubMedCentral

134.

Kontou P, Chatzika K, Pitsiou G, Stanopoulos I, Argyropoulou-Pataka P, Kioumis I: Pharmacokinetics of ciprofloxacin and its penetration into bronchial secretions of mechanically ventilated patients with chronic obstructive pulmonary disease. Antimicrob Agents Chemother. 2011, 55 (9): 4149-4153.PubMedPubMedCentral

135.

Fish DN, Piscitelli SC, Danziger LH: Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies. Pharmacotherapy. 1995, 15 (3): 279-291.PubMed

136.

Gasser TC, Ebert SC, Graversen PH, Madsen PO: Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function. Antimicrob Agents Chemother. 1987, 31 (5): 709-712.PubMedPubMedCentral

137.

Pea F, Poz D, Viale P, Pavan F, Furlanut M: Which reliable pharmacodynamic breakpoint should be advised for ciprofloxacin monotherapy in the hospital setting? A TDM-based retrospective perspective. J Antimicrob Chemother. 2006, 58 (2): 380-386.PubMed

138.

Jones EM, McMullin CM, Hedges AJ, Lovering AM, White LO, Reeves DS, MacGowan AP: The pharmacokinetics of intravenous ciprofloxacin 400 mg 12 hourly in patients with severe sepsis: the effect of renal function and intra-abdominal disease. J Antimicrob Chemother. 1997, 40 (1): 121-124.PubMed

139.

Gous A, Lipman J, Scribante J, Tshukutsoane S, Hon H, Pinder M, Mathivha R, Verhoef L, Stass H: Fluid shifts have no influence on ciprofloxacin pharmacokinetics in intensive care patients with intra-abdominal sepsis. Int J Antimicrob Agents. 2005, 26 (1): 50-55.PubMed

140.

Fish DN, Bainbridge JL, Peloquin CA: Variable disposition of ciprofloxacin in critically ill patients undergoing continuous arteriovenous hemodiafiltration. Pharmacotherapy. 1995, 15 (2): 236-245.PubMed

141.

Roberts DM, Roberts JA, Roberts MS, Liu X, Nair P, Cole L, Lipman J, Bellomo R, RENAL Replacement Therapy Study Investigators: Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. Crit Care Med. 2012, 40 (5): 1523-1528.PubMed

142.

van Geijlswijk IM, van Zanten AR, van der Meer YG: Reliable new high-performance liquid chromatographic method for the determination of ciprofloxacin in human serum. Ther Drug Monit. 2006, 28 (2): 278-281.PubMed

143.

Sousa J, Alves G, Campos G, Fortuna A, Falcao A: First liquid chromatography method for the simultaneous determination of levofloxacin, pazufloxacin, gatifloxacin, moxifloxacin and trovafloxacin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2013, 930: 104-111.PubMed

144.

Al-Ghazawi M, AbuRuz S: Determination of ciprofloxacin in dried blood spots for therapeutic drug monitoring. Chromatographia. 2010, 71 (11/12): 999-1005.

145.

Sun HW, He P, Lv YK, Liang SX: Effective separation and simultaneous determination of seven fluoroquinolones by capillary electrophoresis with diode-array detector. J Chromatogr B Analyt Technol Biomed Life Sci. 2007, 852 (1–2): 145-151.PubMed

146.

Zeng H-J, Yang R, Liu B, Lei L-F, Li J-J, Qu L-B: Simple and sensitive determination of sparfloxacin in pharmaceuticals and biological samples by immunoassay. J Pharmaceutical Analysis. 2012, 2 (3): 214-219.

147.

Wenisch JM, Meyer B, Fuhrmann V, Saria K, Zuba C, Dittrich P, Thalhammer F: Multiple-dose pharmacokinetics of daptomycin during continuous venovenous haemodiafiltration. J Antimicrob Chemother. 2012, 67 (4): 977-983.PubMed

148.

Falcone M, Russo A, Venditti M, Novelli A, Pai MP: Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2013, 57 (11): 1568-1576.PubMed

149.

Pea F, Crapis M, Cojutti P, Bassetti M: Daptomycin underexposure in a young intravenous drug user who was affected by life-threatening Staphylococcus aureus-complicated skin and soft tissue infection associated with bacteraemia. Infection. 2014, 42 (1): 207-210.PubMed

150.

Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL: Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis. 2010, 50 (12): 1568-1574.PubMed

151.

Falcone M, Russo A, Cassetta MI, Lappa A, Tritapepe L, d’Ettorre G, Fallani S, Novelli A, Venditti M: Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary?. J Infect Chemother. 2013, 19 (4): 732-739.PubMed

152.

Safdar N, Andes D, Craig WA: In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother. 2004, 48 (1): 63-68.PubMedPubMedCentral

153.

Bazoti FN, Gikas E, Skoutelis A, Tsarbopoulos A: Development and validation of an ultra performance liquid chromatography-tandem mass spectrometry method for the quantification of daptomycin in human plasma. J Pharm Biomed Anal. 2011, 56 (1): 78-85.PubMed

154.

Craig WA: Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis. 1995, 22 (1–2): 89-96.PubMed

155.

Li C, Du X, Kuti JL, Nicolau DP: Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother. 2007, 51 (5): 1725-1730.PubMedPubMedCentral

156.

Rayner CR, Forrest A, Meagher AK, Birmingham MC, Schentag JJ: Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clinical Pharmacokinet. 2003, 42 (15): 1411-1423.

157.

Cattaneo D, Orlando G, Cozzi V, Cordier L, Baldelli S, Merli S, Fucile S, Gulisano C, Rizzardini G, Clementi E: Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with gram-positive infections. Int J Antimicrob Agents. 2013, 41 (6): 586-589.PubMed

158.

Pea F, Viale P, Cojutti P, Del Pin B, Zamparini E, Furlanut M: Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother. 2012, 67 (8): 2034-2042.PubMed

159.

Schentag JJ: Antimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance. J Chemother. 1999, 11 (6): 426-439.PubMed

160.

Zelenitsky SA, Ariano RE: Support for higher ciprofloxacin AUC 24/MIC targets in treating Enterobacteriaceae bloodstream infection. J Antimicrob Chemother. 2010, 65 (8): 1725-1732.PubMed

161.

Scaglione F: Can PK/PD be used in everyday clinical practice. Int J Antimicrob Agents. 2002, 19 (4): 349-353.PubMed

162.

Rodvold KA, Neuhauser M: Pharmacokinetics and pharmacodynamics of fluoroquinolones. Pharmacotherapy. 2001, 21 (10 Pt 2): 233S-252S.PubMed

163.

Moore RD, Lietman PS, Smith CR: Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987, 155 (1): 93-99.PubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/14/288/prepub

Title: How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?
Authors: Gloria Wong
Fekade Bruck Sime
Jeffrey Lipman
Jason A Roberts
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: BMC Infectious Diseases / Issue 1/2014
Electronic ISSN: 1471-2334
DOI: https://doi.org/10.1186/1471-2334-14-288

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2014

A peptide fragment from the human COX3 protein disrupts association of Mycobacterium tuberculosisvirulence proteins ESAT-6 and CFP10, inhibits mycobacterial growth and mounts protective immune response

Trends and correlates of HIV-1 resistance among subjects failing an antiretroviral treatment over the 2003–2012 decade in Italy

Prevalence and trends of markers of hepatitis B virus, hepatitis C virus and human Immunodeficiency virus in Argentine blood donors

How to treat severe infections in critically ill neutropenic patients?

Empirical antifungal therapy with an echinocandin in critically-ill patients: prospective evaluation of a pragmatic Candida score-based strategy in one medical ICU

Tuberculosis mortality: patient characteristics and causes

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page